scispace - formally typeset
A

Anu Mahadevan

Researcher at Virginia Commonwealth University

Publications -  33
Citations -  2089

Anu Mahadevan is an academic researcher from Virginia Commonwealth University. The author has contributed to research in topics: Cannabinoid receptor & Cannabinoid. The author has an hindex of 25, co-authored 32 publications receiving 1960 citations.

Papers
More filters
Journal ArticleDOI

Multiple pathways involved in the biosynthesis of anandamide

TL;DR: In macrophages, the endotoxin-induced synthesis of anandamide proceeds uniquely through the phospholipase C/phosphatase pathway, and conversion of synthetic NAPE to AEA by brain homogenates from wild-type and NAPE-PLD(-/-) mice can proceed through both the PLC/ph phosphatase and Abdh4 pathways.
Journal ArticleDOI

CB1 cannabinoid receptor-mediated modulation of food intake in mice

TL;DR: The results strongly suggest that CB1 receptors may play a role in regulation of feeding behavior and that SR141716A may affect the actions of endogenous cannabinoids in regulating appetite.
Journal ArticleDOI

Development of the first potent and specific inhibitors of endocannabinoid biosynthesis.

TL;DR: The first potent and specific inhibitors of the biosynthesis of 2-AG that may be used as pharmacological tools to investigate the biological role of this endocannabinoid are reported.
Journal ArticleDOI

Highly selective CB(1) cannabinoid receptor ligands and novel CB(1)/VR(1) vanilloid receptor "hybrid" ligands.

TL;DR: The activities of the seven compounds in vivo did not correlate with their activities at either CB( 1) or VR(1) receptors, thus suggesting the existence of other brain sites of action mediating some of their neurobehavioral actions in mice.
Journal ArticleDOI

The monoacylglycerol lipase inhibitor JZL184 suppresses inflammatory pain in the mouse carrageenan model

TL;DR: Results suggest that the selective monoacylglycerol lipase (MAGL) inhibitor JZL184 reduces inflammatory nociception through the activation of both CB1 and CB2 receptors, with no evidence of tolerance following repeated administration of low doses.